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ScienceDirectNovel strategies are being researched to discover vaccines to
prevent and treat HIV-1. Non-efficacious preventative vaccine
approaches include bivalent recombinant gp120 alone, HIV
gene insertion into an Adenovirus 5 (Ad5) virus vector and the
DNA prime/Ad5 boost vaccine regimen. However, the ALVAC-
HIV prime/AIDSVAX1 B/E gp120 boost regimen showed
31.2% efficacy at 3.5 years, and is being investigated as clade
C constructs with an additional boost. Likewise, although
multiple therapeutic vaccines have failed in the past, in a non-
placebo controlled trial, a Tat vaccine demonstrated immune
cell restoration, reduction of immune activation, and reduced
HIV-1 DNA viral load. Monoclonal antibodies for passive
immunization or treatment show promise, with VRC01 entering
advanced clinical trials.
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Introduction
Despite early optimism about immunological approaches
to prevent and treat human immunodeficiency virus
(HIV), after more than three decades there are no li-
censed HIV preventative or therapeutic vaccines. This
paper outlines the path toward novel vaccine designs that
employ active and passive immunization strategies to
prevent HIV acquisition, and the efforts toward a thera-
peutic vaccine (Figure 1).Current Opinion in Virology 2016, 17:104–109 Preventative HIV-1 vaccines
Initial HIV vaccines using recombinant envelope proteins
Following the traditional vaccine paradigm, the HIV-1
preventative vaccine field first developed over 20 differ-
ent recombinant envelope proteins from various strains in
the late 1980s to mid-1990s, hoping to induce neutralizing
antibodies to HIV. The two recombinant gp120 vaccines
tested in phase 3 were bivalent subtype B/B and bivalent
subtype B/E, but neither proved efficacious [1,2].
What emerged from early immunogenicity studies was
that although these vaccines induced both binding and
neutralizing antibodies, the latter were often limited to
the strain used in the vaccine [3]. This narrow neutraliz-
ing response is because of auto-reactivity and deletion of
the precursor B cells that lead to the development of
broadly reactive neutralizing antibodies [4]. Interestingly,
post hoc analyses suggested that persons with high levels
of blocking and binding antibodies may have had some
protection from acquisition, a finding of minimal interest
until the RV144 trial [5].
Adenovirus 5 (Ad5) vector HIV vaccine
The failure of the recombinant envelope vaccines shifted
the focus to immune responses that would achieve cross-
strain breadth. Emphasis was placed upon vaccines that
induced CD8+ T-cell responses to HIV-1, in the hope
that they would be directed at conserved regions of HIV
and therefore be effective across different populations
and clades. Pathogenesis studies revealed that the mag-
nitude and breadth of the early CD8+ T-cells markedly
influenced early viral control, so cytotoxic T-cell (CTL)-
based vaccines were designed primarily to control post-
infection viremia, but there were also hopes they could
prevent HIV acquisition. The strategy to induce CTL
responses to HIV proteins was to insert HIV genes into
recombinant viral vectors and shuttle these genes into the
Class I antigen-presenting pathway [6].
The first T-cell vaccine candidate to undergo clinical
efficacy trials was a replication-defective recombinant
Ad5 vector with HIV-1 clade B gag/pol/nef inserts. It
had promising non-human primate data and exceptional
human immunogenicity. Containing no envelope genes,
this vaccine tested the concept of whether a CD8+ T-cell
response would reduce post-acquisition viremia. It was
given as three injections (0, 1, 6.5 months) in two phase 2b
trials starting in 2004 (‘Step’) and 2007 (‘Phambili’). Laterwww.sciencedirect.com
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Major advances in the path toward novel vaccine designs.in 2007, when futility was declared for the efficacy objec-
tive of Step, both Step and Phambili discontinued enrol-
ment and vaccination, unblinding participants and
continuing safety follow up.
Both trials revealed unexpected findings. The Step data,
in men who have sex with men (MSM), showed that
vaccine-recipients with pre-existing immunity to Ad5
and/or who were uncircumcised had an increased risk
of HIV-1 acquisition which waned with time [7]. Pham-
bili, conducted in heterosexual adults, showed no vaccine
effect on HIV acquisition during blinded follow-up, but
during the unblinded follow-up there was higher HIV-1
[8] phenomenon could not be attributed to circumcision
status or baseline Ad5 sero-positivity [9]. The mecha-
nism of increased HIV-1 acquisition has not been deci-
phered [10].
Step had further repercussions because it was found that
the vaccine produced what were felt to be reasonable
levels of CD8+ T-cell responses as well as long-standing
immune responses recognizing clades B and C, with no
effect on HIV-1 acquisition or viral load set-point. Post
hoc analysis indicated that these CD8+ immune
responses were directed at variable, not conserved,
regions of the virus. Hence ‘immune T-cell breadth’,www.sciencedirect.com like neutralizing antibody breadth, was still an issue that
needed to be solved [11].
DNA and Ad5 vector — another T-cell based approach
Shortly after Step was initiated, a strategy was developed to
prime Ad5 with DNA. Incorporating vaccine strains from
every major HIV-1 clade, it attempted to overcome the
antibody and T-cell breadth problems. The DNA vaccine
(0, 1, 2 months) contained a mixture of six plasmids
expressing clade B gag, pol, nef and env proteins from
clades A, B, and C, followed by a Ad5 vector boost (month
6) expressing a clade B gag-pol fusion protein and env
glycoproteins from clades A, B, and C. The non-human
primate model demonstrated protection from low-dose
mucosal challenge [12]. The Phase 2A human clinical
study, HVTN 204 demonstrated CD4+ T-cell responses
to HIV-1 envelope, little neutralizing antibodies, but eli-
cited binding antibodies to gp41 and HIV gp120 [13].
HVTN 505 evaluated the regimen in Ad5-seronegative
circumcised MSM. Although increased rates of HIV
acquisition were not seen, there was no efficacy and no
reduction in viral load setpoint [14]. The reasons for
failure are under speculation. Studies reveal that much
of the gp41 antibodies elicited by vaccination were cross-
reactive to an E. coli antigen which may have served as aCurrent Opinion in Virology 2016, 17:104–109
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Development pathway to HIV preventative vaccine licensure in South
Africa.blocking antibody [15]. Recent studies point to viral
escape mechanisms conferring neutralization resistance
[16].
Pox-vector and protein vaccine combination
RV144 (2004–2009) proved that a vaccine approach could
reduce HIV acquisition. It found 60.5% vaccine efficacy
at 1 year and 31.2% vaccine efficacy at 3.5 years with a
canarypox vector prime, ALVAC-HIV (vCP1521) expres-
sing clade E env and clade B gag and pro (0, 1, 3, 6 months)
followed by protein boosts with alum adjuvant, AIDS-
VAX1 clades B/E gp120 (3, 6 months) [17].
In preclinical testing, ALVAC-HIV had been less immu-
nogenic than many other prototypes in human testing
[18,19]. Moreover, the solo use of AIDSVAX1 as well as
a bivalent clade B gp120 had been ineffective in prevent-
ing HIV-1 acquisition [1,2]. That the combination of the
immunogens would reduce HIV-1 acquisition among
heterosexual Thai adults was astonishing.
None of the sera from RV144 recipients, even at peak
levels of antibody response, neutralized a panel of 20 con-
temporaneous isolates of HIV-1 circulating in Thailand
during the course of the trial. However, essentially all
RV144 vaccine-recipients developed binding antibodies
to gp120 [20]. Post-vaccination sera tested against a
linear peptide array derived from an HIV strain used in
both the vector and gp120 exhibited a high binding
pattern to peptides in the V1V2 region, especially the
conserved amino acids on the V1V2 crown, residues 163–
178. Vaccine-recipients with the highest magnitude of
binding antibody titers were more likely to be protected
than those with lower titers, with a reasonably linear
association between vaccine efficacy and the peak con-
centration to the V1V2 scaffold. Epitope mapping of the
antibodies to V1V2 indicated that much of the immune
response was directed at a linear epitope interval includ-
ing a lysine residue at amino acid 169 in the env V2 region.
Antibodies from RV144 vaccine-recipients that bound to
the K169 V2 region did not neutralize nor capture hard-to-
neutralize (tier 2) subtype AE viruses but did bind to env
on tier 2 AE virus-infected CD4+ T cells and mediate
antibody-dependent cellular cytotoxicity (ADCC).
The arising hypothesis is that one mediator of the pro-
tective anti-HIV-1 antibody effector function induced by
the RV144 vaccine was a non-neutralizing and most likely
Fc receptor (FcR)-mediated action that included ADCC
activity. Interestingly, V1V2 responses were not elicited
by the DNA/Ad5 regimen (HVTN 505), even though
these sequences were present in 2 of the 3 envelope
vaccine constructs [21].
Genetic sieve analysis of viral isolates from HIV-infected
participants revealed that isolates from vaccine-recipients
were less likely to possess a lysine at K169 of the env V2Current Opinion in Virology 2016, 17:104–109 region than placebo-recipients, and vaccine efficacy was
significantly higher against HIV-1 manifesting a lysine at
K169 than against HIV-1 with a different residue at
position 169, suggesting vaccine immune pressure at this
region [22]. Thus, the immunological and virological data
concur the V2 region of HIV-1 is a vulnerable point, and a
target site of protective antibodies associated with vac-
cine efficacy of the RV144 regimen.
Building on RV144 (Figure 2)
In 2010, shortly after the announcement of the RV144
results, the pox protein public–private partnership (P5
Partnership) convened to develop the pox-protein regimen
for sub-Saharan Africa. HVTN 097 evaluated the RV144
regimen in South Africa, a different setting to Thailand in
terms of circulating HIV clade, predominant modes of
transmission and average body mass index. Immunologic
response in South Africans was comparable to, if not
slightly better than, responses induced in Thailand [23].
P5 redesigned the ALVAC vector with a clade C env
insert and constructed a bivalent clade C recombinant
gp120. These vaccines are being tested in southern Africa
with two different adjuvants, MF591 and ASO1B, to try
to improve responses and the regimen includes a
12 month boost to extend durability. Pending results
from HVTN 100, a phase 1/2 study, ALVAC/gp120/
MF591 is scheduled for evaluation in a pivotal efficacy
trial in late 2016.
Other prime-boost approaches
Another approach for improving upon RV144 is to use
more immunogenic vector platforms to improve B- andwww.sciencedirect.com
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Table 1
Current therapeutic HIV vaccine approaches
 Inactivated whole virus depleted of gp120
 Single or multiple HIV antigens administered as DNA
 Autologous dendritic cells
 Viral vectors, for example, poxviruses (canarypox ALVAC-HIV,
vCP1452, vCP1433, fowlpox, MVA), adenoviruses (Ad5)T-cell priming, especially to envelope proteins. Investi-
gations into an Ad35 vector platform showed tolerability
and immunogenicity as a prime to Ad5 and as a boost to
DNA immunization [24]. A leading second-generation
vector under development is replication-incompetent
Ad26 in combination with modified vaccinia Ankara
(MVA) and recombinant protein. The vectors contain
novel mosaic inserts designed to elicit cross-clade immu-
nity [6]. Non-human primate studies using Ad26/MVA/
trimeric gp140/ASO1B adjuvant demonstrated protection
from mucosal challenge. Envelope-specific non-neutral-
izing binding antibodies are the main correlates of pro-
tection in these animals.
Neutralizing antibodies
The lack of broadly neutralizing antibodies elicited by the
RV144-like regimens is an acknowledged deficiency in their
immune profile. A concerted international effort is research-
ing immunogens that will elicit broader neutralizing anti-
bodies. The trimeric structure of HIV, defining masking
epitopes and eliminating them from a potential vaccine
immunogen, and using sequential heterologous isolates to
‘coax’ the immune system toward the development of
broadly neutralizing antibodies are all under study [25].
Antibody-mediated prevention: monoclonal antibody
approaches
Passive immunization is the administration of antibodies
to prevent infection. Antibodies have been isolated which
can neutralize a broad range of HIV strains in vitro, raising
hopes for antibody-mediated prevention (AMP) of HIV.
The first antibody to enter advanced human clinical trials
is VRC01, discovered in an elite viral controller [26]. It is a
human monoclonal antibody targeting the HIV-1 CD4
binding site. VRC01 demonstrated protection in animal
studies, and has acceptable human safety [27]. HVTN
703 will investigate the effectiveness of VRC01 and the
level of neutralizing activity required in reducing HIV
acquisition.
Therapeutic vaccines
Even if only partially effective, therapeutic vaccines may
be valuable for HIV-infected individuals as treatment
intensification on the immune system and viral reservoir
when combined with highly active antiretroviral therapy
(HAART), as a safeguard during suboptimal adherence,
and/or as a cure adjunct. Vaccination at the time of
primary infection or early in the course of infection has
been proposed to limit reservoir establishment and pro-
mote viral eradication, analogous to the rationale for early
HAART initiation. Unfortunately, in the past 20 years,
almost fifty safety, immunogenicity and some efficacy
therapeutic HIV vaccine trials have been evaluated, in
acute, early and chronic HIV infection, and all with
minimal success [28,29]. Newer approaches concentrate
on antigen selection and vaccine delivery systems
(Table 1).www.sciencedirect.com Tat therapeutic HIV vaccine
The Italian National AIDS Center is developing a vac-
cine targeting the HIV-1 transactivator of transcription
(Tat) protein, a key virulence factor which plays critical
roles in HIV gene expression, replication, transmission
and disease progression [30].
Tat-specific antibodies appear to be a possible key to
prevent HIV acquisition and spread. Notably, anti-Tat
antibodies are uncommon in natural infection [31,32] and,
when present, correlate with the asymptomatic state and
lower disease progression [33–35].
Phase 1 preventative and therapeutic studies demonstrat-
ed that Tat vaccination is safe and immunogenic [36–38].
A phase 2 study that was not blinded and did not have
placebo controls suggest that in virologically-suppressed
HAART-treated participants, Tat vaccination induced
restoration of CD4+ and CD8+ T-cell numbers and func-
tional central memory T-cell subsets, of B and natural
killer (NK) cell number and a reduction of immune
activation [39,40]. Crucially, Tat immunization induced
a statistically significant reduction of blood HIV-1 DNA
load that persisted for up to three years post-vaccination.
HIV-1 DNA decay was associated with anti-Tat antibo-
dies and neutralization of Tat-mediated entry of oligo-
meric env in dendritic cells [39,40]. The Phase 3 trials
being developed would benefit from designs that incor-
porated placebo and double-blinding.
Therapeutic HIV antibodies
Broadly neutralizing antibodies offer not only prevention
potential, but also treatment. In early-phase clinical trials,
VRC01 and another human monoclonal antibody,
3BNC117, reduced viral load in HIV-1-infected individ-
uals not on HAART [41,42].
Conclusion
After numerous non-efficacious preventive and therapeu-
tic vaccine candidates, pox/gp120 regimens, monoclonal
antibodies, and Tat vaccines are amongst the latest
approaches for exploration.
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